摘要
目的评价血必净辅助治疗急性重症胰腺炎的的临床疗效和安全性。方法通过计算机检索全面收集全世界关于血必净辅助治疗急性重症胰腺炎的随机对照试验/或半随机对照试验,并辅手工检索和其它检索。按照纳入排除标准纳入文献,由两名研究者独立筛选并提取资料,采用Handbook5.0推荐的质量评价标准评价纳入研究的方法学质量,采用RevMan5.0软件进行统计学处理。结果最终纳入4个研究,包括242例患者。Meta分析结果显示治疗组与对照组相比,在白细胞复常时间[OR=-1.78,95%CI（-2.24,-1.32）]、腹痛消失时间[OR=-1.91,95%CI（-2.19,-1.63）]、腹胀消失时间[OR=-1.88,95%CI（-2.33,-1.43）]和血淀粉酶复常时间[OR=-2.58,95%CI（-3.02,-2.15）]方面存在统计学差异。结论当前研究显示,与对照组相比,治疗组能显著减少急性重症胰腺炎患者的白细胞复常时间、腹痛消失时间、腹胀消失时间和血淀粉酶复常时间。
Objective To asses the effective and safety of xuebijing injection on the treatment of severe acute pancreatitis.Methods We searched related database and identified randomized controlled trials or quasi-randomize controlled trials of xuebijing injection on the treatment of severe acute pancreatitis.we evaluated the quality of the included studies by Handbook 5.0 recommend standard and analyzed data by Cochrane Collaboration＇s RevMan5.0.Results Four randomized controlled trials or quais-randomized controlled trials （n=242） were included.Meta analysis showed that there were difference between two groups in the time of white blood cells normalization [OR=-1.78,95%CI （-2.24,-1.32）],the time of abdominal pain disappearance [OR=-1.91,95%CI（-2.19,-1.63）],the time of abdominal distension disappearance [OR=-1.88,95%CI（-2.33,-1.43）] and the time of serum amylase normalization [OR=-2.58,95%CI （-3.02,-2.15）].Conclusion The current evidence showed that contrast with control group,the treatment group can significant reduce postoperative recurrance the time of white blood cells normalization,the time of abdominal pain disappearance,the time of abdominal distension disappearance and the time of serum amylase normalization.
作者
李德榜
柴琛
曹农
李强
LI De-bang,CHAI Chen,CAO Nong,LI Qiang （Department of General Surgery,the First Hospital of Lanzhou University,Lanzhou 730000,China）
出处
《医学信息》
2010年第20期3773-3776,共4页
Journal of Medical Information
关键词
血必净
急性重症胰腺炎
系统评价
xuebijing injection
severe acute pancreatitis
systematic review
